CGD gene therapy (Indiana University)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameCGD gene therapy (Indiana University)
Drug Alias NameMSCV-h91Neochronic granulomatous disease therapy (Indiana University)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionNADPH Oxidase 2 stimulants
TargetsNADPH Oxidase 2
Therapy Area/IndicationsGranulomatous Disease, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIndiana University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIndiana University
Active IndicationsN/A
Inactive IndicationsGranulomatous Disease, Chronic

Other Information

ATC CodeN/A
Related LinksN/A